Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Mazandaran University of Medical Sciences

Iran

Country: Iran

Ownership: Private

Established: 1988-01-01

Employees: -

Market Cap: -

Website: http://wwww.mazums.ac.ir

Clinical Trials

Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial

Not Applicable

Conditions: Coronavirus Infections

Interventions: Biological: Convalescent Plasma

First Posted Date: 2020-03-31

Last Posted Date: 2020-03-31

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT04327349

Locations: 🇮🇷
Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of

Thrombolysis Outcome in Ischemic Stroke

Completed

Conditions: Mortality
Thrombolytic Therapy
Stroke, Acute
Alteplase

First Posted Date: 2020-03-16

Last Posted Date: 2020-07-09

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 214

Registration Number: NCT04309357

Locations: 🇮🇷
Bu Ali Sina hospital , Mazandarn University of Medical Science, Sari, Iran, Islamic Republic of

Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis

Conditions: Multiple Sclerosis
Hypogammaglobulinemia

First Posted Date: 2020-02-25

Last Posted Date: 2020-07-10

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 170

Registration Number: NCT04283747

Locations: 🇮🇷
Bu Ali Sina hospital, Sari, Iran, Islamic Republic of

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

Phase 2

Completed

Conditions: Prevention
Stroke

Interventions: Drug: Rivaroxaban 2.5 Mg Oral Tablet
Drug: Rivaroxaban placebo tablets

First Posted Date: 2020-02-18

Last Posted Date: 2023-10-19

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 42

Registration Number: NCT04273516

Locations: 🇮🇷
Bou- Ali Sina Hospital, Sari, Mazandaran, Iran, Islamic Republic of

Trigger Point Massage in Chronic Tension Headache

Not Applicable

Completed

Conditions: Tension-Type Headache

Interventions: Other: Massage

First Posted Date: 2020-01-18

Last Posted Date: 2020-01-18

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 80

Registration Number: NCT04232046

Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures

Phase 4

Completed

Conditions: Epilepsy, Idiopathic Generalized

Interventions: Drug: Levetiracetam
Drug: Valproate

First Posted Date: 2019-05-07

Last Posted Date: 2022-02-17

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 103

Registration Number: NCT03940326

Locations: 🇮🇷
Bu Ali Sina Hospital, Sari, Mazandaran, Iran, Islamic Republic of

Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome

Phase 3

Completed

Conditions: Ischemic Stroke
Memantine
Excitotoxicity

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2015-08-28

Last Posted Date: 2020-10-06

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 47

Registration Number: NCT02535611

Selenium and Ischemic Stroke Outcome

Not Applicable

Completed

Conditions: Ischemic Stroke

Interventions: Drug: normal saline
Dietary Supplement: Selenium

First Posted Date: 2015-07-22

Last Posted Date: 2020-01-27

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 44

Registration Number: NCT02505295

Locations: 🇮🇷
Athena Sharifi Razavi, Sari, Mazandaran, Iran, Islamic Republic of

Vitamine D in Multiple Sclerosis

Phase 3

Conditions: Multiple Sclerosis

Interventions: Drug: Vitamin D
Drug: Placebo

First Posted Date: 2013-01-15

Last Posted Date: 2013-01-15

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 240

Registration Number: NCT01768039

Locations: 🇮🇷
Mazandaran University of medical sciences, Sari, Mazandaran, Iran, Islamic Republic of

Study of Zonisamide in Early Parkinson Disease

Phase 2

Withdrawn

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2013-01-11

Last Posted Date: 2022-04-14

Lead Sponsor: Mazandaran University of Medical Sciences

Registration Number: NCT01766128

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy